Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
Spyre Therapeutics launched the SPY772 program, a long-acting coformulation of anti-TL1A and anti-IL-17A/F antibodies, and initiated the Phase 2 SKYLIGHT trial in Hidradenitis Suppurativa. The randomized study will enroll approximately 150 adults to evaluate the efficacy of adding SPY072 to background bimekizumab therapy, with topline HiSCR75 data expected in late 2027 or early 2028.
Key figures
- Phase Of Trial
- Phase 2
- Primary endpoint
- HiSCR75
- Patients enrolled
- 150
- Data readout timing
- late 2027 or early 2028
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.